INTRODUCTION Percutaneous transcatheter aortic valve implantation (TAVI) has become an established therapy for inoperable and high-surgical-risk patients with severe aortic stenosis. Although TAVI in patients with degenerated surgical aortic bioprostheses (i.e. valve-in-valve TAVI) is increasingly reported in Western studies, such data is lacking in Asian patients. We describe the initial experience of valve-in-valve TAVI in Asia.
INTRODUCTION
Percutaneous transcatheter aortic valve implantation (TAVI), also known as transcatheter aortic valve replacement, has become the treatment of choice for inoperable patients with severe aortic valve stenosis (1, 2) and an alternative treatment to open chest surgical aortic valve replacement (SAVR) in patients at high surgical risk. (3, 4) Due to the minimally invasive nature of the technique, valve-in-valve TAVI is increasingly used as an alternative treatment modality in patients with degenerated surgical bioprostheses in the aortic position.
Valve-in-valve TAVI is an attractive option for patients with a previous aortic surgical bioprosthesis; these patients are considered to be at elevated risk for reoperation due to various reasons, including technical difficulties of a scarred chest, advanced patient age and other comorbidities. Several case series, including a large global registry on valve-in-valve TAVI, (5) (6) (7) (8) (9) have been reported. However, such data on Asian patients is lacking. We describe the first case series of valve-in-valve TAVI for degenerated aortic surgical bioprostheses in Asia.
METHODS
Eight consecutive patients who underwent valve-in-valve TAVI in a single centre due to degenerated surgical bioprostheses in the aortic position were included in the study. All patients were evaluated by a multidisciplinary heart team, including two cardiac surgeons, and were deemed to be at elevated risk of redo open heart surgery. Bioprosthetic aortic valve failures were categorised, based on the primary mechanism of failure, into stenotic, regurgitation or mixed (with at least a moderate degree of both stenosis and regurgitation), according to the recommendations of the American Society of Echocardiography. (10) All valve-in-valve TAVI procedures were performed using either the self-expanding CoreValve (Medtronic Inc, Minneapolis, MN, USA) prosthesis (Fig. 1) or the balloon-expandable SAPIEN XT (Edwards Lifesciences, Irvine, CA, USA) prosthesis (Fig. 2) . The CoreValve prosthesis consists of three porcine pericardial leaflets sutured within a self-expanding nitinol frame, whereas the SAPIEN XT prosthesis consists of three bovine pericardial leaflets mounted within a balloon-expandable cobalt chromium frame. Both devices were crimped in the procedure suite and inserted in the delivery catheter. All the procedures were performed via transfemoral arterial access.
Patient characteristics, details of previous surgical bioprostheses, and procedural and clinical outcomes were recorded. Procedural success and all adverse clinical outcomes Percutaneous transcatheter aortic valve implantation for degenerated surgical bioprostheses: the first case series in Asia with one-year follow-up and events were defined according to the Valve Academic Research Consortium-2 consensus document. (11) All patients gave their informed consent for the study.
RESULTS
The mean age of the eight patients was 71.6 ± 13.2 years and 5 (62.5%) were male. Their baseline characteristics are summarised in Table I . Previous surgical valves were all stented bioprostheses in the aortic position, and the majority (n = 7, 87.5%) were Carpentier-Edwards (CE) PERIMOUNT bioprostheses. Of note, the majority of the patients (n = 6, 75.0%) had small surgical prostheses, which were defined as surgical bioprostheses of labelled size ≤ 21 mm with true inner diameter ≤ 20 mm; in the series, the most common size was 21 mm (n = 5, 62.5%). The mean duration to surgical bioprosthesis degeneration was 10.2 ± 4.1 years. For mechanisms of bioprosthesis failure, there was an equal number of patients in the stenotic and mixed groups (n = 3 in each), while the remaining cases (n = 2) were due to regurgitation.
Valve-in-valve TAVI was successfully performed in all patients via the transfemoral approach. The CoreValve prosthesis (Figs. 3 & 4) was used in six patients and the SAPIEN XT prosthesis (Figs. 5 & 6) was used in the remaining two patients. There were no deaths or strokes at 30 days. All patients reported significant improvement in New York Heart Association (NYHA) functional classification status and none required permanent pacemaker implantation after the procedure. The in-hospital, 30-day and one-year haemodynamic and clinical outcomes are shown in Table II .
The overall survival rate at one year was 87.5% (n = 7). The only mortality, which was due to pneumonia, occurred in a patient who had end-stage renal failure on haemodialysis at 11 months after the procedure. For the rest of the patients, post-procedure pressure gradients were maintained at 30 days and one year, with a post-procedure mean pressure gradient (MPG) of 20 ± 11 mmHg and 22 ± 8 mmHg, respectively (Fig. 7) . A significant residual MPG > 20 mmHg was observed in 3 (37.5%) patients. Of these, two patients had CE PERIMOUNT 21-mm valves and one had a CE PERIMOUNT 19-mm valve. Severe patient-prosthesis mismatch (PPM, defined as an indexed effective orifice area < 0.65 cm 2 /m 2 ) occurred in three patients; one of them had a 19-mm PERIMOUNT bioprosthesis and the other two had 21-mm PERIMOUNT bioprostheses. However, all three patients experienced at least one NYHA functional class improvement and none had any cardiac events at one year. Residual aortic regurgitation (AR) of more than mild severity occurred in only 1 (12.5%) patient at 30 days after the procedure. At one year, nearly all (six out of seven) patients had none or trivial residual AR, and only one (i.e. the patient with moderate residual AR at 30 days) had mild residual AR. 
DISCUSSION
Bioprosthetic valves are increasingly used in preference to mechanical valves in open SAVR, as lifelong oral anticoagulation is not required and its attendant complications can be avoided. A recent study has shown similar long-term survival rates in patients with bioprosthetic and mechanical valves. However, patients with bioprosthetic valves require reoperations due to their limited durability and expected degeneration; (12) those undergoing such reoperations face increased surgical risk due to their more advanced age (compared with their age during the index SAVR) during the redo surgery and scarring in the non-virgin chest. Consequently, valve-in-valve TAVI appears to be an attractive, minimally invasive method of replacing the degenerated surgical aortic bioprosthesis without the need for a reoperation. Several small case series and a global registry have shown that it is a feasible and viable option for patients at high risk. (5) (6) (7) (8) (9) In our initial Asian experience of valve-in-valve TAVI in eight patients with degenerated bioprostheses in the aortic position, all procedures were successful, with no mortality or stroke event at 30 days, an 87.5% survival rate at one year, and a single mortality due to a noncardiac cause. The results compare favourably with those of previous studies, which had 30-day mortality rates of 0%-17%, stroke rates of 0%-2%, and a one-year survival rate of 85.8%. (5) (6) (7) (8) (9) Although the majority of our patients (75.0%) had small surgical bioprostheses, the post-procedure 30-day MPG was 20 mmHg, which is similar to that reported in the global registry (mean 16.0 [interquartile range 9.1] mmHg). (8) This is, however, higher than the average expected post-procedure MPG (10 mmHg) for TAVI in a native aortic valve.
( [1] [2] [3] [4] In the present study, the three patients who had a significant post-procedure residual MPG > 20 mmHg previously had small surgical bioprostheses. The three patients with severe PPM also had small surgical bioprostheses (≤ 21-mm PERIMOUNT). The most likely explanation is that these patients already had a high residual MPG and PPM after the initial surgical bioprosthetic valve replacement. (13) Although the TAVI procedure can significantly reduce the pressure gradient, it cannot overcome high baseline pressure gradients or baseline PPM. Larger surgical bioprostheses implanted during the index procedure would reduce baseline PPM and result in better pressure gradients when a valve-invalve TAVI procedure becomes necessary. Although none of our patients with high residual pressure gradients or PPM had any cardiac events at one year, a longer follow-up period was needed to ascertain the clinical impact of PPM.
In the global registry, a residual pressure gradient > 20 mmHg was found in 27% of patients, although small (≤ 21 mm labelled size) surgical bioprostheses accounted for only 29% of their total population. (8, 9) Interestingly, the global registry also observed that the CoreValve prosthesis resulted in a lower pressure gradient in small surgical bioprostheses, compared to the balloonexpandable valve, due to its supra-annular valve design. (8, 9) Our series is too small to draw a similar conclusion; however, based on the global registry experience, the CoreValve prosthesis is currently preferred for aortic valve-in-valve TAVI, particularly if the surgical bioprosthesis is ≤ 21 mm in size.
Only one patient in our series had moderate residual AR at 30 days, which became mild at one year. This patient received a self-expanding transcatheter valve, and it is likely that the continued outward expansion of the frame resulted in better sealing (and thus decreased paravalvular AR) over time. The other surviving patients had none or trivial residual AR. Similarly, this result compares favourably with the global registry, where only 5% of patients had more than mild residual AR. (8, 9) The low rate of post-procedure AR, as compared to native valve TAVI, is likely due to the fact that the surgical bioprosthetic ring is circular and the sewing ring is not heavily calcified, allowing for good apposition of the new TAVI prosthesis within the bioprosthetic ring. This is an important finding, as even mild paravalvular AR after TAVI has been shown to result in reduced longer-term survival globally, as compared to patients with no or trivial paravalvular AR following TAVI in native aortic valves. (3, 14) One limitation of this study is that it was a small retrospective study among a group of highly selected patients. Thus, the results cannot be generalised to all valve-in-valve TAVI procedures in Asian patients. Furthermore, as nearly all our patients were implanted with a single model of surgical bioprosthesis, results may differ in patients with other types of surgical aortic bioprostheses.
In conclusion, we reported the initial Asian experience of valve-in-valve TAVI for degenerated surgical aortic bioprostheses. Valve-in-valve TAVI was successfully performed in eight patients without adverse events at 30 days; good clinical and NYHA: New York Heart Association haemodynamic outcomes were sustained at one year. Valvein-valve TAVI appears to be a feasible, relatively safe and less invasive alternative therapy for Asian patients with degenerated surgical aortic valve bioprostheses. At the initial SAVR, the largestpossible bioprosthesis should be implanted (> 21 mm labelled size) to allow for a better haemodynamic profile if a subsequent valve-in-valve TAVI becomes necessary. These findings may provide an impetus to employ more bioprostheses, rather than mechanical valves, in younger patients undergoing open SAVR in the near future, given that this effective technique of replacing a failed surgical bioprosthesis is available.
